<DOC>
	<DOC>NCT00413010</DOC>
	<brief_summary>The primary objective of this study is to evaluate the efficacy of pregabalin as compared to placebo in the treatment of patients with general anxiety disorder (GAD). Efficacy will be measured by the improvement in the total Hamilton Anxiety Rating Scale (HAM-A) scores from baseline observed following 8 weeks of double-blind treatment or at earlier termination during the double-blind treatment phase and analyzed using a mixed linear model for repeated measures.</brief_summary>
	<brief_title>Pregabalin in the Treatment of Patients With Generalized Anxiety Disorder (GAD).</brief_title>
	<detailed_description>Further enrollment in this study was stopped on January 28, 2008 based on the recommendation of an independent data monitoring committee. The recommendation to stop the study was not based on any safety findings.</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Adult male and female subjects with primary DSMIV diagnosis of GAD, as confirmed by the MINI structured interview. Historical failure to respond optimally to a GAD treatment Current primary DSMIV (Diagnostic and Statistical Manual of Mental Disorders 4th edition) diagnosis of major depressive disorder with or without seasonal pattern, dysthmic disorder, depressive disorder NOS (not otherwise specified), social phobia, panic disorder with or without agoraphobia, post traumatic stress disorder, dissociative disorder, borderline personality disorder, obsessivecompulsive disorder, antisocial personality disorder, as defined in the DSMIV TR (Diagnostic and Statistical Manual of Mental Disorders 4th edition, Text Revision). Past and/or current DSMIV diagnosis of schizophrenia, schizoaffective disorder, other psychotic disorders, bipolar disorders (I or II), factitious disorder or cognitive disorder (including delirium, dementia, and amnestic disorder).</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2009</verification_date>
</DOC>